NewsMV
(Nasdaq: CELC) has appointed David W. Gryska to its Board of Directors, a move announced on October 2, 2026, as the biotechnology company transitions into a commercial-stage enterprise.
The appointment coincides with the recent FDA approval of the company's first product, REVTORPYK (gedatolisib), for the treatment of advanced breast cancer.
Brian Sullivan, Chief Executive Officer and co-founder of Celcuity, stated that Gryska's addition to the board is timely given the company's shift toward commercialization.
Sullivan noted that Gryska brings over 35 years of strategic and financial leadership experience in the life sciences industry, including specific expertise in advising early-stage biotechnology companies.
Keep reading